S J Goldie

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability
    April D Kimmel
    Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Cost Eff Resour Alloc 10:12. 2012
  2. pmc Health and economic impact of rotavirus vaccination in GAVI-eligible countries
    Sun Young Kim
    Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    BMC Public Health 10:253. 2010
  3. pmc Cost-effectiveness of Rotavirus vaccination in Vietnam
    Sun Young Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    BMC Public Health 9:29. 2009
  4. pmc Economic evaluation of pneumococcal conjugate vaccination in The Gambia
    Sun Young Kim
    Department of Health Policy and Management, Harvard School of Public Health, Center for Health Decision Science, Boston, MA, USA
    BMC Infect Dis 10:260. 2010
  5. ncbi request reprint A refined estimate of the average lifetime cost of pelvic inflammatory disease
    Jennifer M Yeh
    Department of Health Policy and Management, Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115 5924, USA
    Sex Transm Dis 30:369-78. 2003
  6. ncbi request reprint Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Obstet Gynecol 103:619-31. 2004
  7. ncbi request reprint A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 106:896-904. 2003
  8. ncbi request reprint Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115 5924, USA
    J Natl Cancer Inst 96:604-15. 2004
  9. ncbi request reprint Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
    Sue J Goldie
    Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Am J Med 115:632-41. 2003
  10. ncbi request reprint Health economics and cervical cancer prevention: a global perspective
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, 2nd floor Boston, MA 02115 5924, USA
    Virus Res 89:301-9. 2002

Detail Information

Publications98

  1. pmc Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability
    April D Kimmel
    Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA
    Cost Eff Resour Alloc 10:12. 2012
    ..abstract:..
  2. pmc Health and economic impact of rotavirus vaccination in GAVI-eligible countries
    Sun Young Kim
    Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    BMC Public Health 10:253. 2010
    ..Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries...
  3. pmc Cost-effectiveness of Rotavirus vaccination in Vietnam
    Sun Young Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    BMC Public Health 9:29. 2009
    ..g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection), and assess the influence of the features on the cost-effectiveness of rotavirus vaccination...
  4. pmc Economic evaluation of pneumococcal conjugate vaccination in The Gambia
    Sun Young Kim
    Department of Health Policy and Management, Harvard School of Public Health, Center for Health Decision Science, Boston, MA, USA
    BMC Infect Dis 10:260. 2010
    ..Our objective was to assess the potential impact of PCVs of different valences in The Gambia...
  5. ncbi request reprint A refined estimate of the average lifetime cost of pelvic inflammatory disease
    Jennifer M Yeh
    Department of Health Policy and Management, Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115 5924, USA
    Sex Transm Dis 30:369-78. 2003
    ..The major complications of pelvic inflammatory disease (infertility, ectopic pregnancy, and chronic pelvic pain) are the leading cause of non-HIV sexually transmitted disease morbidity in the United States...
  6. ncbi request reprint Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Obstet Gynecol 103:619-31. 2004
    ..To evaluate the cost-effectiveness of human papillomavirus (HPV) DNA testing as a primary screening test in combination with cervical cytology in women aged 30 years or more...
  7. ncbi request reprint A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 106:896-904. 2003
    ..These include a better understanding of the heterogeneity of vaccine response, the effect of type-specific vaccination on other HPV types and the degree to which vaccination effect persists over time...
  8. ncbi request reprint Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115 5924, USA
    J Natl Cancer Inst 96:604-15. 2004
    ..We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 vaccine in a population with an organized cervical cancer screening program...
  9. ncbi request reprint Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
    Sue J Goldie
    Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Am J Med 115:632-41. 2003
    ..To explore the cost-effectiveness of interventions to improve adherence to combination antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection...
  10. ncbi request reprint Health economics and cervical cancer prevention: a global perspective
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, 2nd floor Boston, MA 02115 5924, USA
    Virus Res 89:301-9. 2002
    ....
  11. ncbi request reprint Cost-effectiveness of HPV 16, 18 vaccination in Brazil
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, United States of America
    Vaccine 25:6257-70. 2007
    ....
  12. ncbi request reprint A potential error in evaluating cancer screening: a comparison of 2 approaches for modeling underlying disease progression
    Sue J Goldie
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115 5924, USA
    Med Decis Making 23:232-41. 2003
    ..Evaluating cancer screening often requires modeling the underlying disease process and not observed disease, particularly in the absence of direct evidence linking screening to a survival benefit...
  13. ncbi request reprint Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness
    S J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Suite 2, Boston, MA 02115 5924, USA
    JAMA 285:3107-15. 2001
    ..Cervical cancer is a leading cause of cancer-related death among women in developing countries. In such low-resource settings, cytology-based screening is difficult to implement, and less complex strategies may offer additional options...
  14. ncbi request reprint The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women
    S J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard University School of Public Health, Boston, Massachusetts 02115 5924, USA
    Ann Intern Med 130:97-107. 1999
    ..Women with HIV infection have a higher risk for cervical squamous intraepithelial lesions than do women without HIV infection, and the optimal regimen for cervical cancer screening in these women is uncertain...
  15. ncbi request reprint The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men
    S J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass 02115 5924, USA
    JAMA 281:1822-9. 1999
    ..Homosexual and bisexual men infected with human immunodeficiency virus (HIV) are at increased risk for human papillomavirus-related anal neoplasia and anal squamous cell carcinoma (SCC)...
  16. ncbi request reprint Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus
    S J Goldie
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115-5924, USA
    Am J Med 111:140-9. 2001
    ....
  17. pmc Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults
    B R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass, USA
    Am J Public Health 91:1456-63. 2001
    ..This study was designed to examine the societal cost-effectiveness and the impact on government payers of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults...
  18. ncbi request reprint Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance
    Jane J Kim
    Department of Health Policy and Management, Harvard Center for Risk Analysis, 718 Huntington Ave, Second Floor, Boston, MA 02115, USA
    JAMA 287:2382-90. 2002
    ..Every year approximately 2 million US women are diagnosed as having a cervical cytological result of atypical squamous cells of undetermined significance (ASC-US)...
  19. ncbi request reprint Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness
    M C Weinstein
    Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115-5924, USA
    Ann Intern Med 134:440-50. 2001
    ..Primary resistance testing also seems to be reasonably cost-effective and will become more so as the prevalence of primary resistance increases...
  20. ncbi request reprint Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    J Natl Cancer Inst 97:888-95. 2005
    ..We assessed the cost-effectiveness of incorporating HPV DNA testing into existing cervical cancer screening programs in the United Kingdom, The Netherlands, France, and Italy...
  21. ncbi request reprint Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults
    Bruce R Schackman
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Arch Intern Med 162:2478-86. 2002
    ....
  22. ncbi request reprint Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness
    Felicitas C Kuehne
    Harvard Program on the Economic Evaluation of Medical Technology, 718 Huntington Ave, Second Floor, Boston, MA 02115 5924, USA
    Arch Intern Med 162:2545-56. 2002
    ..Hepatitis C virus (HCV) is an important cause of liver disease in human immunodeficiency virus (HIV)-infected patients...
  23. pmc The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting
    J J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Program in Health Decision Science, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, USA
    Br J Cancer 97:1322-8. 2007
    ..In a resource-constrained setting such as Brazil, our results support that the first priority in reducing cervical cancer mortality should be to vaccinate pre-adolescent girls...
  24. ncbi request reprint Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS
    Bruce R Schackman
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Med Decis Making 22:27-38. 2002
    ....
  25. pmc Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States
    Jane J Kim
    Department of Health Policy and Management, Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Ann Intern Med 151:538-45. 2009
    ..The role of vaccination against HPV types 16 and 18, which is recommended routinely for preadolescent girls, is unclear in this age group...
  26. pmc The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico
    Delphine Hu
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS ONE 2:e750. 2007
    ..S. Although national efforts have been made to improve maternal services in the last decade, it is unclear if Millennium Development Goal 5--to reduce maternal mortality by three-quarters by 2015--will be met...
  27. ncbi request reprint Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines
    Sue J Goldie
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115 5924, USA
    Arch Intern Med 162:921-8. 2002
    ....
  28. ncbi request reprint The cost-effectiveness of air bags by seating position
    J D Graham
    Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    JAMA 278:1418-25. 1997
    ..Motor vehicle crashes continue to cause significant mortality and morbidity in the United States. Installation of air bags in new passenger vehicles is a major initiative in the field of injury prevention...
  29. ncbi request reprint Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly
    D N Fisman
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Clin Infect Dis 32:419-30. 2001
    ..In the absence of prospective clinical trials, debridement and retention is a reasonable strategy for treatment of older persons with staphylococcal or streptococcal infection and a nonloosened prosthesis...
  30. pmc Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA
    H E Hsu
    Harvard Medical School, Boston, MA, USA
    HIV Med 12:97-108. 2011
    ..The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infected women of childbearing age in the USA...
  31. ncbi request reprint Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis
    Delphine Hu
    Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Ann Intern Med 141:501-13. 2004
    ..Clinical guidelines have traditionally advised annual Chlamydia trachomatis screening for women younger than 25 years of age...
  32. ncbi request reprint Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients
    April D Kimmel
    Division of General Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Antivir Ther 10:41-52. 2005
    ..Guidelines regarding the frequency of CD4 cell count and HIV RNA monitoring in HIV-infected patients vary, with recommended strategies ranging from every 2 to every 6 months...
  33. pmc Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal
    Elena Losina
    Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS Med 6:e1000173. 2009
    ..Our objective was to project the clinical impact and cost-effectiveness of interventions to prevent LTFU from HIV care in West Africa...
  34. ncbi request reprint Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Diseases and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 43:S113-8. 2006
    ..Adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds...
  35. ncbi request reprint Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong
    Jane J Kim
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    J Public Health (Oxf) 26:130-7. 2004
    ..To assess the cost-effectiveness of alternative cervical cancer screening strategies to inform the design and implementation of a government-sponsored population-based screening programme in Hong Kong...
  36. ncbi request reprint Assessing preferences for prevention versus treatment using willingness to pay
    Phaedra S Corso
    Harvard University School of Public Health, USA
    Med Decis Making 22:S92-101. 2002
    ..Information from opinion polls suggests citizens favor spending a higher proportion of all health care dollars on prevention rather than treatment...
  37. pmc HIV drug resistance surveillance for prioritizing treatment in resource-limited settings
    Rochelle P Walensky
    Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    AIDS 21:973-82. 2007
    ..Sentinel testing programs for HIV drug resistance in resource-limited settings can inform policy on antiretroviral therapy (ART) and drug sequencing...
  38. doi request reprint Cost-effectiveness analysis of alternative first-trimester pregnancy termination strategies in Mexico City
    D Hu
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    BJOG 116:768-79. 2009
    ....
  39. ncbi request reprint Preference-based measures in economic evaluation in health care
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Annu Rev Public Health 21:587-611. 2000
    ..Widespread acceptance of the methodology likely awaits more consensus on measurement techniques, as well as educational efforts in the public health and medical communities on the usefulness of the approach...
  40. pmc Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV
    Nicole G Campos
    Program in Health Policy, Harvard University, Cambridge, Mass, USA
    Am J Med 120:272-9. 2007
    ..Our objective was to use these data to examine the cost-effectiveness of treating HCV in an urban cohort of co-infected patients...
  41. ncbi request reprint Mathematical models of cervical cancer prevention in the Asia Pacific region
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:M17-29. 2008
    ....
  42. ncbi request reprint Mathematical models of cervical cancer prevention in Latin America and the Caribbean
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:L59-72. 2008
    ..If the cost per vaccinated girl is less than I$25 HPV-16/18 vaccination would be very cost-effective in all 33 countries; for it to be affordable, costs may need to be lower...
  43. ncbi request reprint Multiparameter calibration of a natural history model of cervical cancer
    Jane J Kim
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Epidemiol 166:137-50. 2007
    ..The authors found that leveraging primary data from longitudinal studies provides unique opportunities for model parameterization of the unobservable nature of HPV infection and its role in the development of cervical cancer...
  44. pmc Keeping the noise down: common random numbers for disease simulation modeling
    Natasha K Stout
    Program in Health Decision Science, Harvard School of Public Health, 718 Huntington Ave, Boston, MA 02115, USA
    Health Care Manag Sci 11:399-406. 2008
    ..We provide a tutorial introduction and demonstrate the application of common random numbers in an individual-level simulation model of the epidemiology of breast cancer...
  45. ncbi request reprint The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality
    George R Seage
    Department of Epidemiology and Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Acquir Immune Defic Syndr 30:421-8. 2002
    ....
  46. pmc Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination
    Jeremy D Goldhaber-Fiebert
    Department of Health Policy and Management, Harvard School of Public Health, Boston, USA
    Popul Health Metr 5:11. 2007
    ..S. policy choices for cervical cancer prevention, we developed a model of human papillomavirus (HPV) and cervical cancer, explicitly incorporating uncertainty about the natural history of disease...
  47. pmc Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves
    Sun Young Kim
    Program in Health Decision Science, Health Policy and Management Department, Harvard School of Public Health, Boston, MA 02115, USA
    Bull World Health Organ 85:833-42. 2007
    ..We sought to describe a method that explicitly considers both a health-care programmes cost-effectiveness and its affordability. For illustration, we apply the method to the programme to vaccinate infants against hepatitis B in the Gambia...
  48. pmc Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results
    Jennifer M Yeh
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    Int J Cancer 124:157-66. 2009
    ..These results illustrate the potential promise of a gastric cancer screening program and provide rationale for urgent clinical studies to move the prevention agenda forward...
  49. pmc Trade-offs in cervical cancer prevention: balancing benefits and risks
    Natasha K Stout
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave, Second Floor, Boston, MA 02115, USA
    Arch Intern Med 168:1881-9. 2008
    ....
  50. pmc Health and economic implications of HPV vaccination in the United States
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 359:821-32. 2008
    ..The cost-effectiveness of prophylactic vaccination against human papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for guidelines for immunization in the United States...
  51. ncbi request reprint Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa
    Chara E Rydzak
    MD PhD Program in Health Policy, Harvard Medical School, Boston, MA 02115, USA
    Sex Transm Dis 35:775-84. 2008
    ..We assess the cost-effectiveness of on-site prenatal syphilis screening with newly available rapid point-of-care screening tests in sub-Saharan Africa...
  52. doi request reprint Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy
    Jane J Kim
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 26:4015-24. 2008
    ..e., <$5 per dose), and screening is offered at older ages...
  53. doi request reprint Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
    Sue J Goldie
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 26:4080-93. 2008
    ....
  54. ncbi request reprint Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias
    Karen M Kuntz
    Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 22:218-27. 2002
    ..This analysis provides a general framework to determine when issues of heterogeneity may be important...
  55. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  56. pmc Modeling cervical cancer prevention in developed countries
    Jane J Kim
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Vaccine 26:K76-86. 2008
    ..The objective of this review is to highlight points of consensus and qualitative themes, to discuss the areas of divergent findings, and to provide insight into critical decisions related to cervical cancer prevention...
  57. pmc Packaging health services when resources are limited: the example of a cervical cancer screening visit
    Jane J Kim
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 3:e434. 2006
    ....
  58. ncbi request reprint Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  59. doi request reprint Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Reprod Health Matters 16:86-96. 2008
    ..Concerns about financial costs and affordability highlight the need for lowering vaccine prices, cost-efficient mechanisms for delivery of vaccinations to adolescents, and creative sources of financing...
  60. doi request reprint Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam
    Sun Young Kim
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA, USA
    Med Decis Making 30:E1-E28. 2010
    ....
  61. ncbi request reprint A therapeutic HIV vaccine: how good is good enough?
    Rochelle P Walensky
    Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, MA 02114, USA
    Vaccine 22:4044-53. 2004
    ..91 months (cost-effectiveness ratio US$ 45,500/QALY). Even modestly effective therapeutic HIV vaccines may produce small but meaningful increases in life expectancy and compare favorably to alternative uses of scarce HIV care resources...
  62. pmc Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis
    Sue J Goldie
    Center for Health Decision Science, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000264. 2010
    ....
  63. pmc Taking account of future technology in cost effectiveness analysis
    Joshua A Salomon
    Department of Population and International Health, Harvard School of Public Health, Harvard Center for Population and Development Studies, 9 Bow Street, Cambridge MA 02138, USA
    BMJ 329:733-6. 2004
  64. doi request reprint Development of an empirically calibrated model of gastric cancer in two high-risk countries
    Jennifer M Yeh
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:1179-87. 2008
    ..As better data become available, the model can be refined and recalibrated, and, as such, be used as an iterative tool to assess the likely health and economic outcomes associated with gastric cancer prevention strategies...
  65. ncbi request reprint Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease
    Paul E Sax
    Division of Infectious Disease and the Partners AIDS Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 39:69-77. 2005
    ..Because of the high cost of ENF compared with other antiretroviral agents, our objectives were to determine the potential long-term clinical impact and cost-effectiveness of ENF in these patients...
  66. ncbi request reprint Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
    Joshua A Salomon
    Harvard Center for Population and Development Studies, Cambridge, Mass 02138, USA
    JAMA 290:228-37. 2003
    ..Approximately 2.7 million US individuals are chronically infected with the hepatitis C virus (HCV). As public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage...
  67. pmc Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer
    Jennifer M Yeh
    Center for Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer 116:2941-53. 2010
    ..The objective of this study was to estimate the clinical benefits and cost-effectiveness of treatment and endoscopic surveillance to prevent gastric cancer...
  68. ncbi request reprint Cost-effectiveness of cervical-cancer screening in five developing countries
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, Boston, USA
    N Engl J Med 353:2158-68. 2005
    ..Cervical-cancer screening strategies that involve the use of conventional cytology and require multiple visits have been impractical in developing countries...
  69. pmc Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
    Jane J Kim
    Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science, 718 Huntington Avenue, Boston, MA 02115, USA
    BMJ 339:b3884. 2009
    ..To assess the cost effectiveness of including preadolescent boys in a routine human papillomavirus (HPV) vaccination programme for preadolescent girls...
  70. pmc Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections
    Jennifer M Yeh
    Center for Health Decision Science, Harvard School of Public Health, 718 Huntington Avenue, 2nd Floor, Boston, MA 02115, USA
    Cancer Causes Control 20:2021-9. 2009
    ..Our aim was to (1) retrospectively estimate the effects of Helicobacter pylori (H. pylori) and smoking on past gastric cancer incidence and (2) project how interventions on these two risk factors can reduce future incidence...
  71. ncbi request reprint The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies
    Delphine Hu
    Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts 02138, USA
    Sex Transm Dis 33:428-36. 2006
    ..To understand the potential impact of assumptions about the natural history of untreated Chlamydia trachomatis on the cost-effectiveness of screening strategies...
  72. ncbi request reprint Chapter 19: Cost-effectiveness of cervical cancer screening
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 24:S3/164-70. 2006
    ..Despite differences in methods and assumptions, this paper identifies the qualitative themes that are consistent among studies, and highlights important methodological challenges and high-priority areas for further work...
  73. ncbi request reprint Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling
    Sue J Goldie
    Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Vaccine 24:S3/155-63. 2006
    ....
  74. ncbi request reprint Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire
    E Losina
    Departments of Biostatistics and Epidemiology, School of Public Health, Boston University, Boston, MA, USA
    S Afr Med J 96:526-9. 2006
    ..To estimate incidence rates of opportunistic diseases (ODs) and mortality for patients with and without a history of OD among HIV-infected patients in Côte d'Ivoire...
  75. ncbi request reprint Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Infect Dis 41:1316-23. 2005
    ..Our objective was to determine the clinical impact and cost-effectiveness of genotype resistance testing for treatment-naive patients with chronic HIV infection...
  76. ncbi request reprint Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy
    Rochelle P Walensky
    Division of Infectious Disease and the Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Acquir Immune Defic Syndr 31:27-37. 2002
    ..These results can assist decision makers and those planning clinical trials in defining evidence-based performance measures for primary HIV infection treatment and future trials...
  77. ncbi request reprint The cost effectiveness of gonorrhea screening in urban emergency departments
    Julia E Aledort
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
    Sex Transm Dis 32:425-36. 2005
    ..The prevalence of gonorrhea (GC) among adolescent and young women attending some urban emergency departments (EDs) ranges from 1% to 7%, but historically screening has not been logistically practical...
  78. ncbi request reprint Predictors of hazardous child seating behavior in fatal motor vehicle crashes: 1990 to 1998
    E Wittenberg
    Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
    Pediatrics 108:438-42. 2001
    ..This study identifies factors associated with the seating of children in the front seats of vehicles involved in fatal crashes between 1990 and 1998...
  79. pmc Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery
    G Zanetti
    Channing Laboratory, Brigham and Women s Hospital, and Eastern Massachusetts CDC Prevention Epicenter, Boston, USA
    Emerg Infect Dis 7:820-7. 2001
    ..Data on vancomycin's impact on resistance are needed to quantify the trade-off between individual patients' improved clinical outcomes and lower costs and the future long-term consequences to society...
  80. ncbi request reprint State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards
    Mira Johri
    Department of Health Administration, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
    Med Care 40:429-41. 2002
    ..The 54 state AIDS Drug Assistance Programs (ADAP) provide medications to HIV-infected persons with limited resources. Eligibility and coverage vary, raising concerns about health inequities...
  81. pmc Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination
    Jeremy D Goldhaber-Fiebert
    Doctoral Program in Health Policy, Decision Science Concentration, Harvard University, Cambridge, MA, USA
    J Natl Cancer Inst 100:308-20. 2008
    ....
  82. ncbi request reprint Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States
    David N Fisman
    City of Hamilton Social and Public Health Services Department, McMaster University, Hamilton, Ontario, Canada
    Sex Transm Dis 29:608-22. 2002
    ....
  83. ncbi request reprint Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    Antivir Ther 7:257-66. 2002
    ..To estimate the treatment and health care costs of HIV infection or AIDS in France during the era of highly active antiretroviral therapy (HAART)...
  84. ncbi request reprint The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women
    Bruce R Schackman
    Divisions of Outcomes and Effectiveness, Department of Public Health, Weill Medical College of Cornell University, New York, NY 10021, USA
    AIDS 18:1827-34. 2004
    ....
  85. ncbi request reprint HPV communication: review of existing research and recommendations for patient education
    Rebecca Anhang
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    CA Cancer J Clin 54:248-59. 2004
    ....
  86. ncbi request reprint Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis
    Yazdan Yazdanpanah
    Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Faculte de Medecine de Lille, France
    AIDS 19:1299-308. 2005
    ..In 2000, WHO/UNAIDS recommended co-trimoxazole prophylaxis for persons at early stages of HIV infection (WHO stage > or = 2) in sub-Saharan Africa...
  87. pmc Cost-effectiveness of alternative blood-screening strategies for West Nile Virus in the United States
    Caroline T Korves
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    PLoS Med 3:e21. 2006
    ..WNV can be transmitted by blood transfusion, and mandatory screening of blood for WNV was recently introduced throughout the US. Guidelines for selecting cost-effective strategies for screening blood for WNV do not exist...
  88. ncbi request reprint Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS)
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
    J Natl Cancer Inst 98:92-100. 2006
    ..We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations...
  89. ncbi request reprint The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany
    Uwe Siebert
    Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT University of Health Sciences, Medical Informatics and Technology, Hall i T, Austria
    Eur J Public Health 16:185-92. 2006
    ..We sought to develop and validate a decision-analytic model for the natural history of cervical cancer for the German health care context and to apply it to cervical cancer screening...
  90. ncbi request reprint Introducing HPV vaccine in developing countries--key challenges and issues
    Jan M Agosti
    Global Health Program, Bill and Melinda Gates Foundation, Seattle, USA
    N Engl J Med 356:1908-10. 2007
  91. ncbi request reprint Cost-effectiveness analysis of treatment strategies for Stage I and II endometrial cancer
    Janice S Kwon
    Department of Obstetrics and Gynecology, University of Western Ontario, London
    J Obstet Gynaecol Can 29:131-9. 2007
    ..We evaluated the cost-effectiveness of two common strategies for managing early endometrial cancer as part of an Ontario population-based study...
  92. ncbi request reprint Empirically calibrated model of hepatitis C virus infection in the United States
    Joshua A Salomon
    Global Programme on Evidence for Health Policy, World Health Organization, Geneva, Switzerland
    Am J Epidemiol 156:761-73. 2002
    ..These findings have important implications both for individual clinical decisions and for broader public health policy...
  93. ncbi request reprint Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes
    Geoffrey P Garnett
    Department of Infectious Disease Epidemiology, Imperial College London, St Mary s Campus, Norfolk Place, London, UK
    Vaccine 24:S3/178-86. 2006
    ..To date, model results are consistent in predicting a useful role for vaccine, but further epidemiological data are required to help test the validity of models...
  94. ncbi request reprint Economic evaluation of weight loss interventions in overweight and obese women
    Larissa Roux
    Department of Community Health Sciences, University of Calgary, Canada
    Obesity (Silver Spring) 14:1093-106. 2006
    ..To conduct a clinical and economic evaluation of outpatient weight loss strategies in overweight and obese adult U.S. women...
  95. pmc Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment
    Bruce R Schackman
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Health Care Financ Rev 26:67-80. 2005
    ....
  96. ncbi request reprint Rationing decisions and individual responsibility for illness: are all lives equal?
    Eve Wittenberg
    MGH Institute for Technology Assessment, Massachusetts General Hospital, Boston 02114, USA
    Med Decis Making 23:194-211. 2003
    ..This survey measured individuals' rationing allocation choices for situations in which patients are deemed to hold personal responsibility for their diseases and the influence of different arguments on such choices...
  97. ncbi request reprint Blood screening for west nile virus: the cost-effectiveness of a real-time, trigger-based strategy
    Caroline T Korves
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Clin Infect Dis 43:490-3. 2006
    ..A newly proposed, real-time, trigger-based screening strategy was analyzed and was also shown to be not cost-effective. These results were highly sensitive to pricing of screening assays...
  98. ncbi request reprint News media coverage of human papillomavirus
    Rebecca Anhang
    Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Suite 2, Boston, MA 02115 5924, USA
    Cancer 100:308-14. 2004
    ....

Research Grants7

  1. Clinical & Cost-Effectiveness of Cervical CA Screening
    Sue Goldie; Fiscal Year: 2002
    ..The proposed analyses will provide important information to clinicians, public health providers, and policy makers in both the national and international arena. ..
  2. Clinical & Cost-Effectiveness of Cervical CA Screening
    Sue Goldie; Fiscal Year: 2003
    ..The proposed analyses will provide important information to clinicians, public health providers, and policy makers in both the national and international arena. ..
  3. Clinical & Cost-Effectiveness of Cervical CA Screening
    Sue Goldie; Fiscal Year: 2004
    ..The proposed analyses will provide important information to clinicians, public health providers, and policy makers in both the national and international arena. ..
  4. Clinical & Cost Effectiveness of HPV Vaccination in the US
    Sue Goldie; Fiscal Year: 2007
    ....
  5. Clinical & Cost Effectiveness of HPV Vaccination in the US
    Sue Goldie; Fiscal Year: 2008
    ....
  6. Clinical & Cost Effectiveness of HPV Vaccination in the US
    Sue Goldie; Fiscal Year: 2009
    ....
  7. Clinical & Cost Effectiveness of HPV Vaccination in the US
    Sue Goldie; Fiscal Year: 2009
    ....